AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36276997 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery (failed)
Number of subjects: 738
Study 34095882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowpea-based feeds (CpF, n=20)
Number of subjects: 58
Study 34095882 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-based feeds (InF, n=20)
Number of subjects: 58
Study 34095882 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeds (ConF, n=18)
Number of subjects: 58
Study 35621877 — intervention group
Group type: COMPARATOR
Intervention: No anti-HBV regimen (ZDV + intrapartum nevirapine and 1 week of TDF-FTC)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC regimen (3TC + ZDV + LPV/r)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC-TDF regimen (FTC + TDF + LPV/r)
Number of subjects: 138
Study 35621877 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HBeAg positive status
Number of subjects: 138
Study 36250881 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) technique with long volar plate
Number of subjects: 54
Study 32988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 102
Study 32988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 102
Study 32988903 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 102
Study 32988903 — intervention group
Group type: COMPARATOR
Intervention: First-generation EGFR TKIs (gefitinib or erlotinib)
Number of subjects: 102
Study 36274035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Number of subjects: 9
Study 36274035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 34402717 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol supplementation for 30 days
Number of subjects: 0
Study 35231185 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit
Number of subjects: 82
Study 35231185 — intervention group
Group type: COMPARATOR
Intervention: GetActive
Number of subjects: 82
Study 32321518 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Number of subjects: 3354
Study 32321518 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily salmeterol/fluticasone (SFC) 50/500 μg
Number of subjects: 3354
Study 32321518 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured by SGRQ score
Number of subjects: 3354
Study 32321518 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured by CAT score
Number of subjects: 3354
Study 32321518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnoea assessed via eDiary
Number of subjects: 3354
Study 36189735 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational program for breastfeeding
Number of subjects: 40
Study 36189735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 33139143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted stewardship intervention including education on guideline-based treatment, tests of antimicrobial treatment, implementation of a clinical treatment algorithm, and audit and feedback.
Number of subjects: 583
Study 33139143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted stewardship intervention
Number of subjects: 583
Study 33139143 — intervention group
Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 583
Study 32717068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates (oBP)
Number of subjects: 2565
Study 32717068 — intervention group
Group type: COMPARATOR
Intervention: Control (matched non-oBP users)
Number of subjects: 2565
Study 36114655 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 6128
Study 36114655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6128
Study 36114655 — intervention group
Group type: EXPERIMENTAL
Intervention: HFsnEF
Number of subjects: 6128
Study 36114655 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF
Number of subjects: 6128
Study 33167078 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A absorption (retinyl palmitate) after soymilk consumption (501 IU vitamin A)
Number of subjects: 20
Study 33167078 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D2 absorption after soymilk consumption (119 IU vitamin D2)
Number of subjects: 20
Study 33167078 — intervention group
Group type: COMPARATOR
Intervention: Correlation of phospholipids and cholesterol ester concentrations with vitamin A concentration
Number of subjects: 20
Study 32499247 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning using ResNet-50 with regression before classification, 3 input PET slices, and ImageNet pretraining.
Number of subjects: 2582
Study 32499247 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning using ResNet-50.
Number of subjects: 2582
Study 32499247 — intervention group
Group type: COMPARATOR
Intervention: Human performance with 3 readers.
Number of subjects: 2582
Study 35916440 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Caregiver Strain Index (MCSI)
Number of subjects: 423
Study 35916440 — intervention group
Group type: EXPERIMENTAL
Intervention: Race as a moderating factor
Number of subjects: 423
Study 35452317 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 30
Study 35452317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 32728026 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deceptive placebos
Number of subjects: 0
Study 35438617 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active lessons for 2 years
Number of subjects: 34
Study 34358272 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Number of subjects: 203
Study 34358272 — intervention group
Group type: EXPERIMENTAL
Intervention: Music/self-care
Number of subjects: 203
Study 34358272 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care
Number of subjects: 203
Study 34358272 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation/CBT
Number of subjects: 203
Study 34358272 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 203
Study 32586394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose LMWH (Enoxaparin 70 IU/kg twice daily)
Number of subjects: 300
Study 32586394 — intervention group
Group type: COMPARATOR
Intervention: Low-Dose LMWH (Enoxaparin 4000 IU once daily)
Number of subjects: 300
Study 32586394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose LMWH
Number of subjects: 300
Study 32586394 — intervention group
Group type: COMPARATOR
Intervention: Low-Dose LMWH
Number of subjects: 300
Study 34125289 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerveldt glaucoma implantation
Number of subjects: 50
Study 34125289 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (TLE)
Number of subjects: 50
Study 32037127 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride for 4 weeks (Phase I)
Number of subjects: 446
Study 32037127 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of amisulpride for 6 additional weeks (Phase II)
Number of subjects: 446
Study 32037127 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine for 6 additional weeks (Phase II)
Number of subjects: 446
Study 35421217 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated agricultural intervention including distribution of micronutrient powders (MNP), poultry, seeds of greens and onions, soap and chlorine solution, and monthly behavior change trainings.
Number of subjects: 1927
Study 35421217 — intervention group
Group type: COMPARATOR
Intervention: Control group (agricultural intervention without additional nutrition-specific and nutrition-sensitive components).
Number of subjects: 1927
Study 35421217 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated agricultural intervention.
Number of subjects: 1927
Study 33914660 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS + CARN (20 mg/kg body weight)
Number of subjects: 5
Study 33914660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 32729921 — intervention group
Group type: EXPERIMENTAL
Intervention: NCDB analyses using Cox proportional hazards regression models for overall survival
Number of subjects: 141
Study 32729921 — intervention group
Group type: EXPERIMENTAL
Intervention: NCDB analyses producing P values for survival
Number of subjects: 141
Study 34578901 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive individualized care by geriatric-experienced care professionals (pathfinders) with nutritional advice, 12-month intervention, up to 7 home visits and 11 phone calls
Number of subjects: 244
Study 34578901 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive individualized care by geriatric-experienced care professionals (pathfinders)
Number of subjects: 244
Study 34578901 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 244
Study 32013882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pb1 (2000 mg/kg Pb (NO3)2)
Number of subjects: 0
Study 32013882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pb2 (10,000 mg/kg Pb (NO3)2)
Number of subjects: 0
Study 32013882 — intervention group
Group type: COMPARATOR
Intervention: Control (CK)
Number of subjects: 0
Study 32013882 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous expression assays in yeast strain Δycf1
Number of subjects: 0
Study 35971859 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioural obesity treatment (FBT)
Number of subjects: 172
Study 35971859 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance interventions (8-month duration)
Number of subjects: 172
Study 35971859 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT and maintenance
Number of subjects: 172
Study 34649532 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL)
Number of subjects: 198
Study 34649532 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (control group)
Number of subjects: 198
Study 33571040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sambucus ebulus L.
Number of subjects: 94
Study 33571040 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 94
Study 34997178 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day ALA
Number of subjects: 92
Study 34997178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 34128813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminders
Number of subjects: 434
Study 34128813 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study 33053078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2g of ginger daily for 90 days
Number of subjects: 103
Study 33053078 — intervention group
Group type: COMPARATOR
Intervention: 1.2g of placebo daily for 90 days
Number of subjects: 103
Study 34176309 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe lounge menus with warning message
Number of subjects: 213
Study 34176309 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe lounge menus with nicotine content
Number of subjects: 213
Study 34176309 — intervention group
Group type: COMPARATOR
Intervention: Waterpipe lounge menus without warning message
Number of subjects: 213
Study 34176309 — intervention group
Group type: COMPARATOR
Intervention: Waterpipe lounge menus without nicotine content
Number of subjects: 213
Study 33313975 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL
Number of subjects: 80
Study 33313975 — intervention group
Group type: COMPARATOR
Intervention: MitraClip-XTR
Number of subjects: 80
Study 34333176 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPEMF
Number of subjects: 55
Study 34333176 — intervention group
Group type: COMPARATOR
Intervention: Sham tPEMF
Number of subjects: 55
Study 35655860 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanized nursing intervention combined with computed tomography (CT) imaging
Number of subjects: 114
Study 35655860 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 114
Study 34129960 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial drugs (quinine, artemisinin combination therapies, and multiple drug combinations)
Number of subjects: 22
Study 34129960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine and its derivatives
Number of subjects: 22
Study 34129960 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin combination therapies
Number of subjects: 22
Study 34129960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple drug combinations
Number of subjects: 22
Study 34129960 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials evaluating drug safety
Number of subjects: 22
Study 32541154 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary KIM-1 indexed for creatinine (uKIM-1/Cr)
Number of subjects: 754
Study 32541154 — intervention group
Group type: COMPARATOR
Intervention: Low urinary KIM-1 indexed for creatinine (uKIM-1/Cr)
Number of subjects: 754
Study 36465660 — intervention group
Group type: COMPARATOR
Intervention: Dim Red Light + Placebo Capsules
Number of subjects: 36
Study 36465660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Alone
Number of subjects: 36
Study 36465660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light + Exercise + Melatonin
Number of subjects: 36
Study 33926657 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valves (BEV)
Number of subjects: 447
Study 33926657 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding valves (SEV)
Number of subjects: 447
Study 33926657 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 447
Study 33926657 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with conscious sedation (CS)
Number of subjects: 447
Study 36103983 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study 36103983 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 33078627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute mindfulness of peace
Number of subjects: 40
Study 33078627 — intervention group
Group type: COMPARATOR
Intervention: 5 minutes of active listening
Number of subjects: 40
Study 34860467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self‐expanding metal stent (FCSEMS)
Number of subjects: 70
Study 34860467 — intervention group
Group type: COMPARATOR
Intervention: Plastic stent (PS)
Number of subjects: 70
Study 34310730 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 70
Study 34310730 — intervention group
Group type: COMPARATOR
Intervention: No EPO treatment
Number of subjects: 70
Study 34310730 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 70
Study 32164535 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenoscope with disposable cap
Number of subjects: 520
Study 32164535 — intervention group
Group type: COMPARATOR
Intervention: Traditional duodenoscope
Number of subjects: 520
Study 35495419 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation
Number of subjects: 207
Study 35495419 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 207
Study 33080122 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5 mA, anode over C3/cathode over FP2) paired with unloaded cycling for 20 minutes, 10 sessions (5 d/wk for 2 weeks)
Number of subjects: 15
Study 33080122 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS paired with unloaded cycling for 20 minutes, 10 sessions (5 d/wk for 2 weeks)
Number of subjects: 15
Study 36394750 — intervention group
Group type: EXPERIMENTAL
Intervention: polyethylene glycol loxenatide injection + metformin
Number of subjects: 40
Study 36394750 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 40
Study 36153539 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-frozen thrombocyte concentrate (DTC)
Number of subjects: 158
Study 36153539 — intervention group
Group type: COMPARATOR
Intervention: Room temperature-stored platelets (RSP)
Number of subjects: 158
Study 34030703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1218
Study 34030703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Number of subjects: 1218
Study 34030703 — intervention group
Group type: COMPARATOR
Intervention: Usual care without any intervention
Number of subjects: 1218
Study 32329237 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief applied behavior analysis (ABA) intervention
Number of subjects: 36
Study 32329237 — intervention group
Group type: COMPARATOR
Intervention: Evaluation and monitoring-only group (Control)
Number of subjects: 36
Study 36203053 — intervention group
Group type: EXPERIMENTAL
Intervention: Running HIIT
Number of subjects: 11
Study 36203053 — intervention group
Group type: COMPARATOR
Intervention: Cycling HIIT
Number of subjects: 11
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 128
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine-XR
Number of subjects: 128
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 128
Study 33230268 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 128
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: NAc-ventral ACC
Number of subjects: 128
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: NAc-thalamus
Number of subjects: 128
Study 33230268 — intervention group
Group type: EXPERIMENTAL
Intervention: NAc-paracingulate gyrus
Number of subjects: 128
Study 32950893 — intervention group
Group type: EXPERIMENTAL
Intervention: RELAXaHEAD app with progressive muscle relaxation (PMR)
Number of subjects: 62
Study 32950893 — intervention group
Group type: COMPARATOR
Intervention: RELAXaHEAD app without PMR (monitored usual care)
Number of subjects: 62
Study 34175572 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (provided balanced information about ethical dilemmas)
Number of subjects: 700
Study 34175572 — intervention group
Group type: COMPARATOR
Intervention: Control group (not provided balanced information)
Number of subjects: 700
Study 33203625 — intervention group
Group type: EXPERIMENTAL
Intervention: PQT (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, polaprezinc 75 mg)
Number of subjects: 158
Study 33203625 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, bismuth potassium citrate 220 mg)
Number of subjects: 158
Study 33203625 — intervention group
Group type: EXPERIMENTAL
Intervention: PQT
Number of subjects: 158
Study 33203625 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing quadruple therapy
Number of subjects: 158
Study 34882169 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of armodafinil
Number of subjects: 328
Study 34882169 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of armodafinil
Number of subjects: 328
Study 34882169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 34882169 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid users
Number of subjects: 328
Study 34882169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonusers of corticosteroids
Number of subjects: 328
Study 33624514 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + peer-befriending
Number of subjects: 56
Study 33624514 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 32799849 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based resistance training program (one set of push-ups, angled-rows, and bodyweight-squats performed every weekday for 12 weeks)
Number of subjects: 60
Study 32799849 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based resistance training program
Number of subjects: 60
Study 32799849 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study 36314769 — intervention group
Group type: EXPERIMENTAL
Intervention: High-priority action plan
Number of subjects: 0
Study 36314769 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-priority action plan
Number of subjects: 0
Study 34485219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus MMT
Number of subjects: 123
Study 34485219 — intervention group
Group type: COMPARATOR
Intervention: MMT (Control)
Number of subjects: 123
Study 35844628 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized messages about health risks and benefits of COVID-19 vaccination, including celebrity endorsements.
Number of subjects: 2621
Study 35844628 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement from Dr. Fauci.
Number of subjects: 2621
Study 34813963 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, goal-oriented text messages regarding dietary choices
Number of subjects: 162
Study 34813963 — intervention group
Group type: COMPARATOR
Intervention: Attention control group receiving text messages about healthy pregnancy, labor, delivery, and early infancy
Number of subjects: 162
Study 35168638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Oseltamivir and Azithromycin
Number of subjects: 0
Study 35168638 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32862403 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED (R)
Number of subjects: 63
Study 32862403 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared LED (IR)
Number of subjects: 63
Study 32862403 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED + Infrared LED (R + IR)
Number of subjects: 63
Study 32862403 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 63
Study 32862403 — intervention group
Group type: COMPARATOR
Intervention: Sham (S)
Number of subjects: 63
Study 35023846 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-supported Moving Forward
Number of subjects: 81
Study 35023846 — intervention group
Group type: COMPARATOR
Intervention: Self-directed Moving Forward
Number of subjects: 81